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Background: Griffithsin is a broad spectrum antiviral lectin that inhibits viral entry and maturation processes
through binding clusters of oligomannose glycans on viral envelope glycoproteins. An efficient, scaleable
manufacturing process for griffithsin active pharmaceutical ingredient (API) is essential for particularly cost-sensitive
products such as griffithsin -based topical microbicides for HIV-1 prevention in resource poor settings. Our previously
published purification method used ceramic filtration followed by two chromatography steps, resulting in a protein
recovery of 30%. Our objective was to develop a scalable purification method for griffithsin expressed in Nicotiana
benthamiana plants that would increase yield, reduce production costs, and simplify manufacturing techniques.
Considering the future need to transfer griffithsin manufacturing technology to resource poor areas, we chose to focus
modifying the purification process, paying particular attention to introducing simple, low-cost, and scalable procedures
such as use of temperature, pH, ion concentration, and filtration to enhance product recovery.
Results: We achieved >99% pure griffithsin API by generating the initial green juice extract in pH 4 buffer, heating the
extract to 55°C, incubating overnight with a bentonite MgCl2 mixture, and final purification with Capto™ multimodal
chromatography. Griffithsin extracted with this protocol maintains activity comparable to griffithsin purified by the
previously published method and we are able to recover a substantially higher yield: 88 ± 5% of griffithsin from the
initial extract. The method was scaled to produce gram quantities of griffithsin with high yields, low endotoxin levels,
and low purification costs maintained.
Conclusions: The methodology developed to purify griffithsin introduces and develops multiple tools for purification
of recombinant proteins from plants at an industrial scale. These tools allow for robust cost-effective production and
purification of griffithsin. The methodology can be readily scaled to the bench top or industry and process components
can be used for purification of additional proteins based on biophysical characteristics.
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Griffithsin (GRFT) is a high mannose targeting lectin
that has shown promise as a microbicide candidate
against viruses with oligomannose-rich envelope glyco-
proteins, such as HIV-1 or HSV-2 [1-4]. GRFT was ori-
ginally isolated from a red alga (Griffithsia sp.) with
native and recombinant forms showing similar antiviral
activity against laboratory strains and primary isolates of
HIV-1 [1,4]. Recombinant forms of GRFT have been
successfully produced in both E. coli and N. benthami-
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unless otherwise stated.quantities of functional GRFT [4,5]. GRFT has shown to
be a safe and effective microbicide against HIV, but
needs to be evaluated in clinical trials [2,6]. The HIV
epidemic is prevalent in many resource-limited or devel-
oping countries and the availability of indigenous manu-
facturing systems for GRFT in those areas could
facilitate large-scale rollout of microbicide product. Cost
and production complexity are factors that must be con-
sidered when manufacturing biologics for extremely
cost-sensitive markets, such as for microbicides in devel-
oping economies.
This communication details our development of a
process to reduce the production cost of GRFT from N.
benthamiana. Currently published industrial scale GRFT
manufacturing uses ceramic filtration followed by two-This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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methods require specialized equipment and increase
production costs. The molecule’s biophysical properties,
and specifically the melting temperature, were taken into
account when developing a new purification method-
ology. GRFT has a melting temperature of 78.8°C and
remains functionally stable at temperatures not tolerated
by many of the contaminating proteins [7,8]. There are
three primary contaminants to contend with when trying
to purify GRFT from N. benthamiana: two production
host-associated, the small and large subunits of
Ribulose-1,5-bisphosphate carboxylase/oxygenase (Ru-
BisCO), and one contaminant from the TMV production
system, TMV coat protein (CP). RuBisCO lacks the ther-
mostability of GRFT at acidic pHs. Therefore, in these
studies we tested heat treatment, under acidic condi-
tions, of our crude plant extracts containing GRFT to
determine if any of the major contaminants could be re-
moved through precipitation/denaturation. The TMV
CP has shown a propensity to self-aggregate under cer-
tain ionic, pH, and temperature conditions. Absorption
by the clay material, bentonite, has been previously used
to purify TMV particles and could potentially be a useful
tool in removal of the coat protein contaminant [9].
Therefore purification methods utilizing altered heat,
pH, ion concentrations, and bentonite filtration were all
tested in an effort to develop a scalable purification
method requiring less specialized equipment. We have
developed a single-step-chromatography purification
method that will decrease the cost and complexity ofFigure 1 Removal of plant protein contaminants from GRFT Extract w
system were harvested at pH4 in sodium acetate buffer and the extract wa
temperatures ranging from room temperature (24°C) to 90°C and centrifug
assessed temperatures were analyzed by SDS-PAGE with coomassie stainin
remain after incubation at room temperature. Once the extracts are heated
except for the target protein GRFT and the TMV coat protein. The composi
from 50 – 80°C, but at 90°C incubation nearly all proteins are precipitated.
in Figure 1.producing large quantities of GRFT, while increasing the
protein recovery. The application of this knowledge on
industrial size purification should further reduce GRFT
cost of production and may be beneficial for production
of other plant-made pharmaceuticals.
Results and discussion
Leaf punches were used to determine the pH and NaCl
concentration parameters that were optimal for extrac-
tion of GRFT and minimal extraction of contaminating
proteins. One dimensional SDS PAGE profiles showed
the optimal extraction pH for GRFT to be pH 4.0. The
addition of 100 mM NaCl showed minimal impact on
the purity of GRFT in the small-scale samples, but from
prior work it is understood that the addition of NaCl
will improve purity as long as it is not deleterious to the
protein of interest especially as scale is increased. There-
fore all subsequent purifications used 100 mM sodium
acetate and 300 mM NaCl pH4 as the extraction buffer.
Analysis of the small scale protein extraction profiles by
SDS-PAGE demonstrates little impact of temperature on
the extract purity, but does show that GRFT maintains
stability in temperatures ranging from 60 – 80°C.
GRFT’s thermostability in heated extracts was further
assessed in larger scale extractions and Figure 1 shows
clearly the impact that heat has on contaminating pro-
teins. Nearly all contaminating proteins aggregated at
temperatures above 50°C (Figure 1), increasing the ex-
tract purity 30 – 40% (Figure 1), while GRFT remains
stable until the extract reaches 90°C.ith Heat. Plants expressing GRFT through a TMV-based expression
s divided into 7 aliquots. Each aliquot was incubated for 15 minutes at
ed to remove any precipitant. Samples of the initial extract and all
g. The initial extract contains multiple contaminating proteins, which
to at least 50°C the majority of contaminating proteins precipitate
tion of the extract remains similar with temperature treatments ranging
Table: Densitometry readings corresponding to SDS-PAGE shown
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extract after heating was the TMV CP. Therefore,
methods for removing the TMV CP were examined.
These included the addition of bentonite and/or MgCl2,
as well as pH and temperature adjustments. The more
acidic extracts pH 4.0 and pH 6.5 showed increased ac-
tivity of bentonite and MgCl2 for removal of CP relative
to the pH 7.0, 8.0, or 9.0 extracts, as long as extracts
were incubated at 4°C (Figure 2). The pH 6.5 extract in
the presence of bentonite and MgCl2 reduced TMV CP
levels by ~55% (Figure 2), but the pH 4.0 extract in the
presence of bentonite and MgCl2 reduced CP contamin-
ation by ~75%. Therefore, pH 4.0 and incubation at 4°C
was used in subsequent purification with bentonite and
MgCl2, but the most effective concentrations of MgCl2
and bentonite remained to be determined.Figure 2 Effects of pH on the activity of MgCl2 and bentonite to remo
(pH 4–5) or tris (pH7-9) buffer depending on the desired pH range and we
proteins in the initial extract and sample 2 represents the proteins after the
extract after it was adjusted to its corresponding pH a) pH 4.0 and b) pH 9
and represented in sample 4. Samples 5–12 represent various temperature
MgCl2 (M), bentonite (B), and bentonite & MgCl2 (MB) Samples 5 & 6 were
at 42°C after treatment with 0.01 M MgCl2. Samples 9 & 10 were incubated
& 12 were incubated overnight at 4°C after the addition of 1 mg/mL bento
represented in Figure 2 with values from three additional gels representing
area represents an extract condition achieving greater than 80% purity of GMultiple concentrations of bentonite and MgCl2 were
investigated in pH 4.0 buffer to determine the optimal
concentration for removal of TMV CP. Bentonite was
added to GRFT extracts at a range of 0 mg/mL
to 10 mg/mL and MgCl2 was added in a range of
0 – 0.1 M with each concentration tested in combin-
ation and separately to determine the most effective
concentration to aggregate TMV. Figure 3 shows that
0.1 M MgCl2 had a similar impact on TMV CP removal
at all bentonite concentrations tested, with bentonite
having a minimal impact on TMV levels in the absence
of MgCl2. Removal of 75 – 95% of TMV CP was
observed with the addition of 0.1 M MgCl2 (Figure 3),
but bentonite in the absence of MgCl2 only removed 10
– 30% of the CP contaminant. The addition of bentonite
and MgCl2 at their most effective concentrations,ve the TMV coat protein. Extracts were harvested in sodium acetate
re visualized using coomassie stained SDS-PAGE. Sample 1 shows the
extract is heated to 55°C and centrifuged. Sample 3 represents the
.0. Sample 3 extracts were centrifuged to remove additional precipitate
, bentonite, or MgCl2 treatments of sample 4 performed in duplicate.
incubated overnight at 42°C. Samples 7 & 8 were incubated overnight
overnight at 4°C with the addition of 1 mg/mL bentonite. Samples 11
nite & 0.01 M MgCl2. Table: Densitometry readings of SDS-PAGE
additional pH values that were explored (pH 6.5, 7.0, 8.0). The shaded
RFT.
Figure 3 Effects of MgCl2 (0, 0.001 M, 0.01 M, 0.1 M) on the protein content of GRFT extracts treated with bentonite. Coomassie stained
SDS-PAGE was used to see gross changes in purity of the GRFT extracts in both a and b. The initial GRFT extract is represented in sample 1 and
subsequent heat & centrifugation step at sample 2. The supernatant was treated with multiple MgCl2 concentrations (samples 5–12) in duplicate
with the corresponding bentonite concentration 0 mg/mL bentonite (a) or 10 mg/mL bentonite (b). The resulting supernatants of overnight
treatment with MgCl2 and/or bentonite are as follows; (3&4) 0 MgCl2 & 0 bentonite, (5&6) 0 MgCl2, (7&8) 0.001 M MgCl2, (9&10) 0.01 M MgCl2,
(11&12) 0.1 M MgCl2. Samples 11 and 12 both show a dramatic reduction in coat protein after treatment with 0.1 M MgCl2 irrespective of the
bentonite concentration. Table: Densitometry readings of SDS-PAGE represented in a and b including two additional bentonite concentrations
not shown. The shaded area represents an extract condition achieving greater than 80% purity of GRFT.
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in their effects on TMV CP removal. The largest reduc-
tion in TMV CP levels was observed in the absence of
bentonite with the addition of 0.1 M MgCl2, reducing
TMV CP contamination by greater than 95% (Figure 3).
Bentonite has been proven to help in the clarification
process of plant extracts and we continued to explore its
impact on purification, but maintain that it has minimal
impact on TMV CP removal from pH 4.0 extracts.
Since the goal was to provide an alternative, less ex-
pensive, and less complex purification method the steps
outlined thus far were implemented on a larger scale
with fewer variables explored. GRFT was extracted and
aliquoted after temperature treatment. GRFT extract ali-
quots were untreated (control) or treated with 0.1 M
MgCl2 and/or 10 mg/mL bentonite and all were incu-
bated overnight at 4°C. Extracts were compared via
SDS-PAGE with densitometry and again showed that
the greatest reduction of TMV occurred in the 0.1 MMgCl2 treatment group (Figure 4A). The pellets correlat-
ing to the specific treatments contained large amounts
of TMV CP likely through forced aggregation and re-
moval during centrifugation. Minimal loss of functional
GRFT is observed in any of the treatment groups when
compared via HIV-1 gp120 binding ELISAs (Figure 4B).
When western blots targeting TMV CP were quantified
by densitometry a reduction of 65% was observed in ex-
tracts treated with MgCl2, which is significantly de-
creased compared to the bentonite-only treated extract
(Figure 4C). The table in Figure 4 shows GRFT purity in
the four extracts ranges from 64 – 82% with the TMV
content of extracts treated with MgCl2 reduced by as
much as 66%.
In an effort to achieve greater than 95% purity of
GRFT a chromatography step was explored. Extracts
were heated to 55°C and treated with MgCl2 or MgCl2
and bentonite overnight after which they were filtered
through a 0.2 μm filter and loaded onto a Capto® MMC
Figure 4 Summary of the effects of 0.1 M MgCl2 and 10 mg/mL bentonite on GRFT extract purity. a) Coomassie stained SDS-PAGE
showing the initial extraction of GRFT (1), subsequent pH adjustment to pH4 (2) and heating to 55°C followed by centrifugation (3). The resulting
supernatant was untreated (control) or treated with MgCl2 and/or bentonite and stirred overnight at 4°C. The following samples are the resulting
supernatants; (4) Control −4°C, (5) 0.1 M MgCl2, (6) 10 mg/mL Bentonite, (7) 0.1 M MgCl2 & 10 mg/mL Bentonite . The following samples are the
resulting pellets after treatment; (8) Pellet - 4°C, (9) Pellet - 0.1 M MgCl2, (10) Pellet - 10 mg/mL Bentonite, (11) Pellet - 0.1 M MgCl2 & 10 mg/mL
Bentonite. b) Comparison of gp-120 binding GRFT concentrations relative to the control sample (4). Determined through a gp-120 binding ELISA
and represented as a percentage of functional GRFT in the control extract. c) Comparison of the TMV coat protein concentration relative to the
control extract. Determined through densitometry measures of TMV specific westerns and represented as a percentage of TMV in the control
extract. b and c both analyzed by a one-way ANOVA with Bonferroni’s multiple comparison test comparing all groups. * represents a post-hoc
test with a p-value < 0.05. Table: Densitometry readings of SDS-PAGE represented in a. The shaded area represents an extract condition achieving
greater than 80% purity of GRFT.
Table 1 Quantification of activity and recovery of GRFT
from the plant extracts
Purification method % gp-120 Binding % GRFT Recovery
Heat and Chromatography 90.19 ± 1.53 92.13 ± 3.29
Heat, MgCl2, Chromatography 80.25 ± 5.08 84.54 ± 6.84
Heat, MgCl2 & Bentonite,
Chromatography
100.8 ± 4.33 87.73 ± 4.82
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exchanger that does not require buffer exchange and
was chosen to help minimize purification steps. After
chromatography trace amounts of TMV can be seen in
SDS gels and western blots in both the untreated-
control and the MgCl2 treated samples with no TMV
contamination observed in the MgCl2 and bentonite
treated extract (Figure 5). Purity of all extracts after
Capto MMC chromatography was greater than 97%,
with the bentonite and MgCl2 treatment group showing
a purity of >99% by SDS-PAGE densitometry. The re-
covery levels and activity of the purified GRFT were
assessed by gp120 binding ELISAs with very good recov-
ery levels achieved in all treatments undergoing MMC
chromatography. A minimum of 84.5% was recovered in
the MgCl2 treated extract after it was purified bychromatography and a maximum recovery of 92.1% was
observed in the control extract that was purified by
chromatography (Table 1). All extracts maintained an
activity level at least 80% of GRFT purified by the previ-
ously published method [4], with GRFT purified by
MgCl2 & bentonite having 100.8 ± 4.33% of the activity
(Table 1). In summary, purification of GRFT from N.
Figure 5 Purity and TMV CP content of GRFT extracts after Capto ™ MMC purification. SDS –PAGE (a) and TMV western blots (b) were
used to visualize purity and TMV contamination. The initial extract (1) contains both GRFT and TMV CP as well as other plant protein
contaminants. Lanes 2–4 were loaded with 15 μg of chromatography purified protein from the extracts that had previously been heated and
treated with: control – no treatment (2), 0.1 M MgCl2 (3), 0.1 M MgCl2 & 10 mg/mL bentonite (4). Included for comparison was 15 μg of GRFT
purified by the previously published methodology O’Keefe et al., [4] (5). Above each lane is the densitometry determined GRFT purity.
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with MgCl2 & bentonite, and Capto® MMC chromatog-
raphy recovered 88% of the GRFT with >99% purity and
100% activity of the original purification method.
Utilizing the information yielded from small scale ex-
periments GRFT was purified at an industrial pilot scale
(>5 kg of plant material) in a GMP ready facility. At this
scale it was necessary to replace all centrifugation steps
with a filter press because of the impracticality of centri-
fugation at scale. Ten liters of extraction buffer was
added to 5 kg of N. benthamiana and the tissue was
ground to yield 11.4 L of initial extract containing
2599.73 mg of GRFT for a total of 519.9 mg of GRFT
per kg of plant material (Table 2). The extract was pH
adjusted, heated, and filter pressed, which removed
TMV CP and purified GRFT to >90% (Figure 6). The
remaining small protein contaminants were removed by
overnight incubation with 10 mg/mL of bentonite and
0.1 M MgCl2 and subsequent filter pressing. The extract
underwent filter press and sterile filtration simultan-
eously and at this stage was >99% pure, and sterile with
only minimal color. It should be noted that the purifica-
tion process could be halted at this point depending on
the application of the process and necessity for >99%
pure colorless product. Capto® MMC chromatography
was used to remove the color and simultaneously affect
a buffer exchange into phosphate buffered saline pH7.4.
Purity was maintained with greater than 99% purity of
the final product and recovery of 66–72.25%, determinedTable 2 gp120 ELISA assessed GRFT recovery during
industrial pilot purification
Sample Green juice Filter press #1 Filter press #2 Eluate
GRFT (mg) 2599.73 1816.34 1576.52 1543.57
% of GJ 79% 68% 66%by densitometry of SDS-PAGE (Figure 6) and gp120
ELISA respectively (Table 2). Because of the GMP-ready
nature of the purification scheme, endotoxin levels were
assessed and found to be 0.20 EU/mL of final product
with a GRFT concentration of 1.20 mg/mL, which
should be sufficiently low depending on the dosage and
administration route (Table 3). In summary, the purifica-
tion method developed for GRFT herein provided a
>99% pure product with >66% recovery while maintain-
ing low endotoxin levels at industrial pilot scale and
could be further scaled without modification to the
process.
Conclusions
GRFT has been described as a promising topical micro-
bicide component with potential to neutralize a broad
range of viruses including HIV-1, Herpes simplex virus
type 2, Japanese encephalitis virus, Hepatitis C virus, and
SARS-CoV [1,2,10-12]. The safety and efficacy profile of
GRFT as an HIV entry inhibitor was demonstrated in
rabbits, on human cells, and in a sensitive murine HSV-
2 susceptibilty assay [2,4,6]. A comprehensive set of
highly promising data confirming the potential for use of
GRFT in HIV prevention and even treatment, has led to
considerable enthusiasm from policy makers and funders
in bringing GRFT-based topical microbicides to clinical
trial [2,4,6,13-16]. We have been motivated to improve
and simplify the GRFT extraction protocol we initially
developed [4] in anticipation of future need to manufac-
ture extremely large amounts of this protein, preferably
in geographic areas where the HIV-1 epidemic has theTable 3 Endotoxin levels in industrial pilot purified GRFT
GRFT Concentration (mg/mL) Endotoxin (EU/mL)
GRFT Final 1.20 0.204
Figure 6 Analysis of industrial pilot scale purification of GRFT. Representation of the purity, by SDS –PAGE a, and TMV CP content, by
western blot b, of GRFT during industrial pilot scale purification. Sample volumes loaded on the gel were normalized to the initial extraction
volume. The initial extract (1) contains both GRFT and TMV CP as well as other plant protein contaminants. The extract was pH adjusted to pH4
(2)heated (3) and filter pressed(4). After which the extract was incubated overnight with MgCl2 and bentonite and simultaneousely filter pressed
and sterile filtered (5). Samples 6–7 are the GRFT final product At 1x volume, 2xvolume and 15 μg of protein. Included for comparison was 1.5 μg
and 3.0 μg of GRFT purified by the previously published methodology O’Keefe et al., [4] (5). The table represents the densitometric measures of
GRFT and TMV protein content in the extracts.
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vector system we use to produce GRFT requires only
modest investment in plant controlled environment
growth facilities, and does not require use of sophisticated
Agrobacterium infiltration methods that are increasingly
used in plant-made pharmaceuticals research. Beyond the
additional regulatory concerns associated with Agrobacter-
ium-launch vector systems, we have found that unaccept-
able levels of bacterial endotoxin contaminate GRFT
extracts when these are used to express GRFT (unpub-
lished data). Endotoxin removal after Agroinfiltration
inserts yet another costly (and relatively inefficient) step in
protein extraction, making the infectious TMV vectored
expression approach more appealing for the extremely
cost-sensitive manufacturing of topical microbicide com-
ponents. Of course, the TMV vectored approach we use
does present a downside in the need to efficiently remove
the contaminating virus and CP from the extracts. The
methodologies we describe in this communication show
facile methods for reduction of TMV CP.We previously produced GRFT in multi-gram quan-
tities in N. benthamiana, but the purification method-
ology used required specialized ceramic filtration
devices, two chromatography techniques, ultrafiltration-
diafiltration and had relatively low recovery from
infected extracts, 30% possibly increasing to 50% [4]. Of
the purification techniques we describe here, using a
combination of heat (55°C), MgCl2 & bentonite, and a
single chromatographic step were most effective. This
three step approach produced GRFT with no loss in
activity or purity, while recovering nearly 90% of the ex-
tracted GRFT. Each step targets various contaminating
proteins within the plant extract. Heating the extract at
55°C removes the majority of the native plant proteins,
which lack the thermostability of GRFT. Exposing the
extract to a combination of MgCl2 and bentonite
removes the TMV CP contaminant, originating from the
TMV expression vector. Bentonite and MgCl2 work in
tandem, with bentonite known to strip coat protein from
the TMV RNA and potentially the MgCl2 causing either
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cleaving the RNA causing aggregation [9,17,18]. Either
mechanism is plausible for the aggregation of TMV in
the plant extract. Our data shows the necessity of both
MgCl2 and bentonite to be present for optimal TMV re-
moval when coupling to a single chromatography step.
Utilizing Capto® MMC resin allows for removal of trace
protein impurities by binding GRFT to the resin and
eluting based upon the isoelectric point of the protein
with unobservable amounts of TMV left in extracts
treated with bentonite and MgCl2. Stripping of the CP
from TMV likely reduces its ability to bind Capto®
MMC resin and allows for less TMV contaminant bind-
ing and co-elution. All of the techniques, heating, cool-
ing, pH adjustment, and chemical additives, used to
purify GRFT are all facile, scaleable and amenable to
technology transfer to facilities in resource poor coun-
tries. In an effort to demonstrate the scaleability and and
amenability of technology transfer the process was per-
formed at pilot scale in a GMP ready industrial facility
with only slight reductions in the recovery, while provid-
ing pure active GRFT with low endotoxin levels. The
methodology maintains increased recovery at scale,
reducing per unit costs of GRFT, which should increase
the availability of GRFT for HIV entry-inhibition in
resource limited settings.
The techniques discussed here can be applied to other
recombinant protein production methods to address
similar protein contaminants such as native plant
proteins, RuBisCO, and TMV CP. Recombinant proteins
purified from transgenic or transiently expressing plants
both can utilize portions of the methodology to remove
contaminating proteins. It is possible that the manufac-
turing process could be further abbreviated with the use
of transgenically expressed GRFT.
In conclusion, purification of GRFT at scale using this
technique should provide multi-kilogram quantities of
GRFT at a low cost with minimal product loss suitable




GRFT was expressed in N. benthamiana using the same
plasmid and methodology described in O’Keefe et al.,
[4]. Briefly, a TMV-based expression vector system
containing the GRFT amino acid sequence was used to
generate infectious RNA transcripts. Infectious tran-
scripts were inoculated on N. benthamiana (~24 days
post sowing) by gentle abrasion.
GRFT extraction – leaf punches
Ten days after inoculation, 8 mm leaf punches were ran-
domly taken from eight N. benthamiana plants. Two leafpunches were homogenized in 200 μL of each extraction
buffer. Extraction buffers ranged from pH 2–10 consist-
ing of 100 mM buffering agent (glycine, sodium acetate,
Tris, sodium phosphate) with and without 100 mM so-
dium chloride. Samples were centrifuged 15,000 × g for
15 minutes and the supernatant removed. The superna-
tants were then treated with the application of 60°C, 70°
C, or 80°C for ten minutes and compared to an ambient
temperature control sample for each buffer.
GRFT extraction – bench scale
Ten days after inoculation, leaf tissue was harvested and
homogenized in the appropriate extraction buffer with a
ratio of 1:2 (Plant tissue (g): Extraction buffer (mL)).
Extraction buffer composition was either 100 mM so-
dium acetate, 300 mM sodium chloride, 20 mM ascorbic
acid, 10 mM sodium metabisulfite for buffers with a pH
range of 4.0 - 6.5 and 100 mM tris-hydrochloride,
300 mM sodium chloride, 20 mM ascorbic acid, 10 mM
sodium metabisulfite for buffers in the pH range of 7.0
-9.0. Extract material was filtered through 4 layers of
cheesecloth and 1 layer of miracloth, heated to the de-
sired temperature for 15 minutes, and centrifuged at
15,000 × g for 15 minutes. In some experiments the
purification process was halted at this point and the ex-
tract tested for purity by SDS PAGE, but in an effort to
remove the TMV coat protein additional alterations were
made to the extract. The semi-pure extract was treated
with 0 – 0.1 M MgCl2 and 0 – 10 mg/mL bentonite at
varying pHs and then incubated at varying temperatures
over night to determine if any combination of bentonite,
MgCl2, pH, and temperature could help remove the coat
protein. After 16 hrs at their specified temperature all
extracts were centrifuged at 15, 000 × g for 15 minutes
and the supernatant removed. Pellets were resuspended
in equivalent volumes of 2× SDS running buffer. Pellet
and supernatant samples were analyzed by SDS-PAGE.
SDS-PAGE with densitometry
Sample buffer (4 X SDS) containing BME was added to
all samples and samples were then boiled at 95°C for
10 minutes. Twenty microliters of sample was loaded on
12% Bis-Tris gels with the addition of 5 μL of protein
ladder to the outer wells. Gels were ran at 200 V for
37 minutes then stained with coomassie stain for 1 hour
and destained for 3 hours. Gels were imaged on a Kodak
Image station 4000R Pro using Carestream SE M soft-
ware. The software was then used to mark the lanes on
the gell and find resulting bands. Bands were analyzed
based on intensity and size. GRFT purity of each sample
was determined based on the band sizes and strength of
contaminating proteins in the same lane. The percentage
of TMV CP or GRFT for each purification step was rela-
tive to the sample representing the step preceding the
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and TMV CP samples are represented as a percentage of
the unmodified control.
GRFT gp120 ELISA
In a 96-well plate, wells were coated with 200 μL of
1 ng/mL gp120 (Protein Sciences, Meriden, CT) in PBS
and incubated overnight at 4°C. Plates were washed with
PBS-T and blocked with 5% PBS-T-M for 2 hours at
room temperature. Wells were washed with PBS-T and
incubated at room temperature for 2 hours with sample
diluted 1:10 in PBS and further diluted in series 1:5
down the plate. Purified GRFT, uninfected plant extract,
PBS sample and no gp120 coating controls were in-
cluded in all ELISAs. Plates were washed and incubated
for 1 hour at room temperature with RB anti-GRFT
serum dilute 1:10,000 in 1% PBS-T-M. After washing the
plate, the secondary antibody, GT anti-rabbit conjugated
to HRP, was added to each well diluted 1:20,000 in 1%
PBS-T-M. Plates were again washed and the ultra sensi-
tive TMB substrate added to each well. After 3 minutes
0.2 M H2SO4 was added to stop the reaction and the
colorimetric change was read at OD 405 nm on a
Beckman- Coulter plate reader. The collected data was
background subtracted and analyzed for the relative
change in GRFT concentration between purification
methods.
TMV western blot
Samples were ran on SDS-PAGE via methodology de-
scribed earlier and then transferred to a PVDF mem-
brane via BioRad transblot turbo system. Membranes
were incubated for 1 hour with 3% PBS-T-M (phosphate
bufferd saline with 0.5% Tween20 and 3% non-fat dry
milk) at room temperature, washed with PBS-T three
times and incubated overnight at4°C with rabbit anti-
body against TMV 1:5000 in 3% PBS-T-M. Blots were
then washed with 3% PBS-T and incubated with goat
anti-rabbit HRP conjugated antibody diluted 1:10,000 in
3% PBS-T-M for 1 hour at room temperature. Blots were
washed and developed with ECL Prime development kit
(GE Lifesciences). Blots were exposed on a Kodak Image
Station 4000 R Pro using Carestream SE M software.
Software was then used to identify and analyze visible
bands based on intensity and size.
Chromatography and purity verification
GRFT extract was purified using an AKTA Purifier with
a XK16 column packed with 10mLs of Capto™ MMC
resin (GE Life Sciences). After overnight incubation the
semi-pure extract was filtered through a 0.2 μm filter
and loaded on to the column at a rate of 5 mL/minute.
A two-step gradient of 90% and 100% phosphate buff-
ered saline (137 mM NaCl, 2.7 mM KCl, 10 mMNaH2PO4, 2 mM KH2PO4) pH7.4 was used to elute
GRFT from the column. Fractions (10 mL) were col-
lected and pooled after being checked for the presence
of GRFT through SDS-PAGE. The purity of the concen-
trated GRFT was verified by an overloaded SDS-PAGE
and a western blot against the TMV CP. The glycan
binding capabilities of the purified GRFT were deter-
mined through gp120 binding. The purified extract was
compared to GRFT purified with the previously pub-
lished methodology in over-loaded SDS-PAGE, western
blots against TMV and gp120 ELISAs.Industrial pilot scale purification
Five days after infectious transcript inoculation, plants
were harvested and the rTMV was isolated. The isolated
rTMV was used to inoculate approximately 600 plants
through high velocity spraying with diatomaceous earth
in a 100 mM phosphate buffer pH 7.4. Ten days after
spray inoculation, five kg of leaf tissue was harvested
and homogenized in extraction buffer (100 mM sodium
acetate, 300 mM sodium chloride, 20 mM ascorbic acid,
10 mM sodium metabisulfite pH4.0) with a ratio of 1:2
(Plant tissue (g): Extraction buffer (mL)). The extract pH
was adjusted back to pH 4.0 and heated to 55°C for
15 minutes. The heated extract was immediately filter
pressed through a 0.3 μm filter (Ertel Alsop, M-853)
with the addition of the filter aid Cell Pure® (30 g/L).
The extract was incubated overnight in a holding tank
with continuous stirring at 4°C with the addition of
10 mg/mL of bentonite and 0.1 M MgCl2. After over-
night incubation the extract was filter pressed again
through a 0.3 μm filter and an inline sterilization filter
(Sartorius, Sartopore 2). Capto® MMC chromatography
was performed as described above, but the resin was
packed in a sterilized AxiChrom 50/300 column. Purity
was assessed via previously discussed methodology of
gp120 ELISA, SDS-PAGE with densitometry, and TMV
western blot with densitometry. Additionally, endotoxin
levels were assessed with the methodology explained
below.Endotoxin analysis
Contaminating endotoxin levels in the final GRFT prod-
uct purified at industrial pilot scale was analyzed with
Charles River Laboratory Endosafe® PTS. Twenty-five μL
of GRFT solution was added to each of the four wells on
a Limulus Amebocyte Lysate Test cartridge and the
endotoxin levels were analyzed accordingly.Statistical analysis
All statistical analysis and summary graphical represen-
tations were performed on Graph Pad Prism® 5.0.
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